Researchers investigate the efficacy of a novel intra-tumoral drug delivery carrier in treating oral squamous cell carcinoma

Car­mot Ther­a­peu­tics has filed to go pub­lic in a chilly en­vi­ron­ment for new list­ings, but the obe­si­ty biotech’s place in one of drug de­vel­op­ment’s hottest

Ole­ma On­col­o­gy, the Bay Area biotech run by for­mer As­traZeneca ex­ec­u­tive Sean Bo­hen, raised $130 mil­lion from a pri­vate place­ment and a cred­it fa­cil­i­ty of